Akari Therapeutics, Plc (AKTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol AKTX
- Company Akari Therapeutics, Plc
- Price $10.7
- Changes Percentage 18.76
- Change 1.69
- Day Low $8.8
- Day High $11.03
- Year High $49.6
- Year Low $3.02
- Market Cap $8,985,008
- Price Avg 50 EMA (D) $10.07
- Price Avg 200 EMA (D) $10.63
- Exchange NASDAQ
- Volume 10,729
- Average Volume 150,524
- Open $8.93
- Previous Close $9.01
- EPS -4.48
- PE -1.75
- Earnings Announcement 2026-12-04 12:00:00
- Shares Outstanding $1,144,587
Company brief: AKARI THERAPEUTICS, PLC (AKTX )
- Healthcare
- Biotechnology
- Dr. Samir Rashmikant Patel M.D.
- https://www.akaritx.com
- GB
- N/A
- 01-06-2014
- US00972G2075
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.